Objective: Among the available mood stabilizers, it appears that lithium may share an important role for treatment of acute mania. In a study from Sep. 2007 to Apr. 2008 at Razi Psychiatric Hospital we evaluated the efficiency of olanzapine vs. lithium.
Methods: Forty (40) female inpatients meeting DSM-IV-TR criteria for acute mania were entered into a 3-week parallel group, double-blind study for random assignment to olanzapine or lithium carbonate in a 1:1 ratio. Primary outcome measurements were the changes in Manic State Rating Scale (MSRS) at baseline and weekly intervals up to the third week. Similarly, overall illness severity was rated using the Clinical Global Impression-Severity of illness scale (CGI-S) at baseline and at the end of the third week. Analysis of the data was accomplished by means of split-plot (mixed) and repeated measures analysis of variance (ANOVA) and t test.
Results: While both olanzapine and lithium were found to be significantly helpful in the improvement of manic symptoms (p<0.05), lithium was considerably more successful by the end of the third week (p<0.0002 and p<0.003, for frequency and intensity of the symptoms). CGI-S also showed important improvements with both olanzapine and lithium (p<0.043 and p<0.015 for olanzapine and lithium).
Conclusion: Though both olanzapine and lithium were effective in the improvement of manic symptoms, lithium was more beneficial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2009.08.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation of the gene polymorphism with psychopathology and predictive antimanic responses in patients with bipolar mania.
Front Pharmacol
November 2024
Department of Psychiatry, Jinhua Municipal Center Hospital, Jinhua, China.
To explore the correlation of the gene polymorphism with psychopathology and predict responses in patients with mania treated with lithium and olanzapine. Sixty patients with bipolar mania were treated with lithium combined with olanzapine for 8 weeks and assessed using YMRS, HAMD, and HAMA. The gene polymorphism rs1800497 was tested.
View Article and Find Full Text PDFInitiation of Antipsychotics During the First Year After First-Episode Psychosis: A Population-Based Study.
Acta Psychiatr Scand
November 2024
Niuvanniemi Hospital, Kuopio, Finland.
Background: Antipsychotics are recommended after first-episode psychosis. Knowledge on the current use patterns in real-world settings is thus important to inform clinical practice. We aimed to describe antipsychotic initiation during 1 year after first-episode psychosis and its associated factors.
View Article and Find Full Text PDFPediatric Bipolar Disorder: Challenges in Diagnosis and Treatment.
Paediatr Drugs
November 2024
Department of Psychiatry, Columbia University Irving Medical Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Despite an opportunity to prevent adult psychopathology associated with bipolar disorder through early diagnosis in children, there is insufficient information and awareness among healthcare providers about the unique features and treatment of mania and its comorbid conditions in children. Converging evidence from disparate sites describe a developmentally distinct presentation of bipolar disorder in youth that is highly morbid, persistent and responds to treatment with the mood stabilizer medications used in the treatment of adult bipolar disorder, such as divalproex sodium and carbamazepine. Some are additionally approved for use in pediatric populations including, for manic or mixed states, risperidone, aripiprazole, and asenapine for those aged 10-17 years and also including lithium and olanzapine for ages 13-17 years.
View Article and Find Full Text PDFComparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes.
CNS Drugs
November 2024
Department of Psychiatry, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, People's Republic of China.
Background: A network meta-analysis was performed to evaluate the risk of congenital malformations and other prenatal outcomes in fetuses after exposure to antipsychotic medications and mood stabilizers during pregnancy.
Methods: We searched the PubMed, EMBASE, and Cochrane CENTRAL databases up to 15 December 2023, to identify experimental and observational studies comparing antipsychotic and mood stabilizer treatments with control treatments (no exposure). The primary outcome of the study was the incidence of congenital malformations and the secondary outcomes were preterm birth and spontaneous abortion.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!